GILEAD SCIENCES, INC. 4

Johanna Mercier, Chief Commercial & Corporate Affairs Officer of Gilead Sciences, Inc., exercised stock options and sold a total of 28,000 GILD common shares for roughly $3.85 million under a Rule 10b5-1 plan on August 17, 2026.

On August 17, 2026, Johanna Mercier, Chief Commercial & Corporate Affairs Officer of Gilead Sciences, Inc., exercised two tranches of non-qualified stock options (23,110 shares at a $66.64 strike and 1,890 shares at a $72.34 strike) and received the underlying common shares, increasing her holdings before subsequent sales. That same day, pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025, she sold 16,530 shares of common stock at an average price of approximately $137.37 and an additional 11,470 shares at an average price of approximately $138.04, for total sale proceeds of roughly $3.85 million. After these transactions, she directly owned 118,234 shares from one line and an additional 69,960 shares from another option-derived position, indicating continued substantial equity exposure despite the monetization of a portion of her holdings through pre-planned sales.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

fda

Accession

0001782135-26-000028

Alert Tier

9